Jan 8 (Reuters) – AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the drugmaker’s previously announced $50 billion research, development and manufacturing investment in the country.
The company announced the investment plan last year in response to President Donald Trump’s tariff policy. The plan includes construction of a $4.5 billion manufacturing facility in Virginia, AstraZeneca’s largest single manufacturing investment globally.
Suarez, who joined AstraZeneca in 1999, has served as country president for Spain since 2020, and has over 20 years of U.S. healthcare experience, the company said.
(Reporting by Shashwat Awasthi in Bengaluru; Editing by Mrigank Dhaniwala)
